Choosing a better end point for trials of bone-protective agents

Ann Oncol. 2015 May;26(5):1032-1033. doi: 10.1093/annonc/mdv039. Epub 2015 Jan 28.

Authors

R Leibowitz-Amit¹, L Khoja², I F Tannock², A M Joshua³

Affiliations

¹ Oncology Institute & Cancer Research Center, Sheba Medical Center, Tel-Hashomer, Israel.
² Princess Margaret Cancer Centre, Toronto, Canada.
³ Princess Margaret Cancer Centre, Toronto, Canada. Electronic address: anthony.joshua@uhn.ca.

PMID: 25632065
DOI: 10.1093/annonc/mdv039

No abstract available

Publication types

Letter
Comment

MeSH terms

Bone Density Conservation Agents / therapeutic use*
Bone Neoplasms / secondary*
Denosumab / therapeutic use*
Humans
Male
Prostatic Neoplasms, Castration-Resistant / pathology*

Substances

Bone Density Conservation Agents
Denosumab